News

Shares in Oxford BioMedica, an Oxford University spin-out, fell 8.3 percent on news that the company was seeking up to £30 million to fund the Phase III trial of its a TroVax cancer immunotherapy product.

US biotechnology firm DOR BioPharma plans to build a bigger force in gastro-intestinal medicines by buying Copenhagen-based Gastrotech Pharma, a spin-out of Gothenburg University in Sweden.

Intercell, an Austrian biotechnology company, has received a $1 million milestone payment from Merck for progress in the development of a bacterial vaccine candidate.

Celoxica, an Oxford University spin-out that makes chip design software, blamed “depressive market” conditions for the company raising less capital than it initially expected in its initial public offering

British drug-delivery company Phoqus blamed "unfavourable market" conditions for meeting only its minimum target of £10 million in its initial public offering.

A spin-out from Sheffield University and Northwick Park Institute for Medical Research says it has created a compound using carbon monoxide that could save lives by helping with organ transplants.

A spin-out from Sheffield that uses stem cells to help with conventional drug discovery is looking for investment to continue pre-clinical research on therapeutic applications and business development activities.

UK-based AMDG's monitor for early detection of heart conditions particularly associated with diabetics is already selling in Germany. Now the company is now looking for support to enter into the US market.

The Cambridge-based company a.gain medical says it has invented the world's first urethral sensor for women – and is looking for further investment.

For her latest fortnightly funding column, Mary Lisbeth D'Amico set out to find European seed funders. That was as easy as finding a needle in a haystack.